Navigation Links
Jack Anthony to Resign From VaxGen's Board After Accepting CEO Position at Osprey Pharmaceuticals

SOUTH SAN FRANCISCO, Calif., Sept. 28 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that Jack Anthony has resigned from the company's Board of Directors as a result of accepting the CEO position at Osprey Pharmaceuticals. The Osprey Board has required that Mr. Anthony relinquish all corporate directorships in accepting this position. Mr. Anthony's resignation is effective immediately.


"On behalf of VaxGen's directors and officers, I want to thank Jack for his service to the company and its stockholders, and for his many contributions to our efforts in pursuit of a strategic transaction," said James P. Panek, VaxGen's President and CEO. "Since his appointment to the Board in May, Jack has lent his active and expert assistance in helping us formulate and consider various strategic alternatives. We wish him the very best, and know that he will be a tremendous asset to Osprey." VaxGen continues to seek qualified independent director candidates who will contribute to its efforts in pursuit of strategic alternatives.

About VaxGen

VaxGen is a biopharmaceutical company based in Brisbane, California. For more information, please visit the company's web site at

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the anticipated filing of the company's outstanding quarterly reports and its application for listing of its common stock. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

SOURCE VaxGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. JT Packard exec resigns after settling copyright disputes
2. Donley resigns as WiCell director
3. UWM accepts resignation of research dean
4. Renaissance Learning CEO resigns to start company
5. Chemical-petroleum executive joins Virent Energy board
6. Schneider National exec joins TrafficCast board
7. Ethics Board site offers welcome contrast to state IT mistakes
8. Genomics researcher Hood joins NimbleGen board
9. Corporate control begins with a strong board
10. Kyron appoints former AMA chairman to board
11. Online service makes board connections
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):